|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC6A9 |
Gene summary for SLC6A9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC6A9 | Gene ID | 6536 |
| Gene name | solute carrier family 6 member 9 | |
| Gene Alias | GCENSG | |
| Cytomap | 1p34.1 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P48067 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6536 | SLC6A9 | HCC1_Meng | Human | Liver | HCC | 7.94e-11 | 3.32e-02 | 0.0246 |
| 6536 | SLC6A9 | HCC1 | Human | Liver | HCC | 5.10e-04 | 1.72e+00 | 0.5336 |
| 6536 | SLC6A9 | HCC2 | Human | Liver | HCC | 1.32e-03 | 1.06e+00 | 0.5341 |
| 6536 | SLC6A9 | S027 | Human | Liver | HCC | 7.33e-06 | 4.55e-01 | 0.2446 |
| 6536 | SLC6A9 | S028 | Human | Liver | HCC | 6.47e-12 | 4.30e-01 | 0.2503 |
| 6536 | SLC6A9 | S029 | Human | Liver | HCC | 6.39e-07 | 3.20e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005507612 | Liver | HCC | transition metal ion homeostasis | 81/7958 | 138/18723 | 8.87e-05 | 7.72e-04 | 81 |
| GO:0042168 | Liver | HCC | heme metabolic process | 30/7958 | 42/18723 | 1.40e-04 | 1.13e-03 | 30 |
| GO:00330131 | Liver | HCC | tetrapyrrole metabolic process | 39/7958 | 59/18723 | 2.14e-04 | 1.63e-03 | 39 |
| GO:00067781 | Liver | HCC | porphyrin-containing compound metabolic process | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
| GO:004691611 | Liver | HCC | cellular transition metal ion homeostasis | 67/7958 | 115/18723 | 4.64e-04 | 3.08e-03 | 67 |
| GO:0042440 | Liver | HCC | pigment metabolic process | 51/7958 | 84/18723 | 5.74e-04 | 3.65e-03 | 51 |
| GO:00000411 | Liver | HCC | transition metal ion transport | 59/7958 | 105/18723 | 3.18e-03 | 1.47e-02 | 59 |
| GO:0006783 | Liver | HCC | heme biosynthetic process | 19/7958 | 27/18723 | 3.18e-03 | 1.47e-02 | 19 |
| GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
| GO:0006779 | Liver | HCC | porphyrin-containing compound biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
| GO:0033014 | Liver | HCC | tetrapyrrole biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
| GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
| GO:0046148 | Liver | HCC | pigment biosynthetic process | 37/7958 | 62/18723 | 4.73e-03 | 2.02e-02 | 37 |
| GO:00068261 | Liver | HCC | iron ion transport | 34/7958 | 58/18723 | 9.66e-03 | 3.63e-02 | 34 |
| GO:005507211 | Liver | HCC | iron ion homeostasis | 47/7958 | 85/18723 | 1.17e-02 | 4.28e-02 | 47 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC6A9 | SNV | Missense_Mutation | novel | c.2048T>A | p.Leu683Gln | p.L683Q | P48067 | protein_coding | tolerated(0.21) | benign(0.312) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SLC6A9 | SNV | Missense_Mutation | c.746G>A | p.Ser249Asn | p.S249N | P48067 | protein_coding | tolerated(0.5) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC6A9 | SNV | Missense_Mutation | novel | c.92N>A | p.Thr31Lys | p.T31K | P48067 | protein_coding | tolerated_low_confidence(0.48) | benign(0.006) | TCGA-EW-A6SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tch | SD |
| SLC6A9 | SNV | Missense_Mutation | novel | c.1001G>A | p.Gly334Glu | p.G334E | P48067 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC6A9 | SNV | Missense_Mutation | novel | c.1686G>T | p.Met562Ile | p.M562I | P48067 | protein_coding | tolerated(0.07) | possibly_damaging(0.908) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC6A9 | SNV | Missense_Mutation | rs755321679 | c.1324N>A | p.Val442Met | p.V442M | P48067 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SLC6A9 | deletion | Frame_Shift_Del | novel | c.1967delN | p.Pro656LeufsTer15 | p.P656Lfs*15 | P48067 | protein_coding | TCGA-VS-A9UZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC6A9 | SNV | Missense_Mutation | rs200036856 | c.395G>A | p.Arg132His | p.R132H | P48067 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SLC6A9 | SNV | Missense_Mutation | c.301G>A | p.Gly101Ser | p.G101S | P48067 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC6A9 | SNV | Missense_Mutation | c.1576N>A | p.Leu526Met | p.L526M | P48067 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GlyT1 PET radiotracers | 21253021 | ||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PMID29338548-Compound-18 | |||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178101423 | ||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PMID29338548-Compound-25 | |||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PF-3463275 | PF-03463275 | ||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | MK-2637 | |||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PMID29338548-Compound-29 | |||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | PMID29338548-Compound-23 | |||
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1169880 | BITOPERTIN | |
| 6536 | SLC6A9 | TRANSPORTER, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178101480 |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |